| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Impairments of property, plant, and equipment | NaN | 0 | 0 | 21,700 |
| Net income | 274,900 | 364,300 | 338,700 | 631,700 |
| Depreciation and amortization | 22,600 | 22,800 | 21,900 | 40,900 |
| Share-based compensation expense | 33,900 | 39,000 | 39,100 | 69,600 |
| Net unrealized losses on equity securities | -61,600 | NaN | NaN | NaN |
| Deferred income taxes | 25,900 | 97,700 | NaN | NaN |
| Other | -32,000 | 33,600 | 100 | -14,000 |
| Accounts receivable | -38,200 | 52,500 | -81,600 | 100,000 |
| Inventories | 40,100 | 16,500 | 17,500 | 18,600 |
| Accounts payable and accrued expenses | -12,700 | 23,200 | 31,200 | 43,500 |
| Other assets and liabilities | -27,000 | 98,200 | -67,200 | 49,900 |
| Net cash provided by operating activities | 463,300 | 346,200 | 562,100 | 652,900 |
| Purchases of property, plant, and equipment | 100,800 | 172,900 | 210,500 | 137,100 |
| Acquired lease intangible assets | NaN | 0 | 5,500 | NaN |
| Deposits | 5,700 | -5,100 | 5,700 | 9,800 |
| Purchases of available-for-sale debt securities | 701,700 | 520,300 | 385,900 | 2,499,200 |
| Maturities of available-for-sale debt securities | 269,000 | 485,500 | 182,500 | 915,900 |
| Sales of available-for-sale debt securities | 1,307,900 | 0 | 596,000 | 1,265,600 |
| Purchase of investment in privately held company | 25,000 | 25,000 | 30,000 | 0 |
| Acquisitions, net of cash acquired | NaN | 0 | NaN | NaN |
| Net cash provided by (used in) investing activities | 743,700 | -227,600 | 140,900 | -464,600 |
| Excise tax paid on net share repurchase | NaN | 0 | 0 | 5,000 |
| Payments of debt issuance costs | NaN | 0 | 0 | 11,500 |
| Payments to repurchase common stock | 1,500,000 | 0 | 1,000,000 | 0 |
| Proceeds from line of credit | NaN | 0 | 0 | 200,000 |
| Repayment of line of credit | 0 | 0 | 0 | 500,000 |
| Proceeds from the exercise of stock options | 68,300 | 99,000 | 40,200 | 34,700 |
| Proceeds from the issuance of stock under espp | 5,600 | 0 | 4,300 | 4,900 |
| Rsus withheld for taxes | 58,300 | 600 | 500 | 15,500 |
| Net cash used in financing activities | -1,484,400 | 98,400 | -956,000 | -292,400 |
| Net (decrease) increase in cash and cash equivalents | -277,400 | 217,000 | -253,000 | -104,100 |
| Cash and cash equivalents, beginning of period | 1,557,100 | 1,340,100 | 1,697,200 | NaN |
| Cash and cash equivalents, end of period | 1,279,700 | 1,557,100 | 1,340,100 | NaN |
UNITED THERAPEUTICS Corp (UTHR)
UNITED THERAPEUTICS Corp (UTHR)